ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 7, 2009, Pages 2200-2205

  Wang, Qiuyan ^a   Mora Jensen, Helena ^b   Weniger, Marc A ^b   Perez Galan, Patricia ^b   Wolford, Chris ^c   Hai, Tsonwin ^c   Ron, David ^d   Chen, Weiping ^a   Trenkle, William ^a   Wiestner, Adrian ^b   Ye, Yihong ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Cancer therapy; ER stress UPR; Histone H2A; Ubiquitin

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; BORTEZOMIB; EEYARESTATIN I; HISTONE H2A; PROTEIN INHIBITOR; PROTEIN NOXA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; GENE EXPRESSION REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; TRANSCRIPTION REGULATION; UBIQUITINATION; UPREGULATION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; HYDRAZONES; HYDROXYUREA; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TRANSCRIPTION, GENETIC; UBIQUITIN;

EID: 60549109872     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807611106     Document Type: Article

References (36)

1. McCracken AA, Brodsky JL (2003) Evolving questions and paradigm shifts in endoplasmic-reticulum-associated degradation (ERAD). BioEssays 25:868-877.
2. Kostova Z, Wolf DH (2003) For whom the bell tolls: Protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. EMBO J 22:2309-2317.
3. Ye Y (2006) Diverse functions with a common regulator: Ubiquitin takes command of an AAA ATPase. J Struct Biol 156:29-40.
4. Adams J (2004) The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360.
5. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cells 5:417-421.
6. Fernandez Y, et al. (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65:6294-6304.
7. Qin JZ, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65:6282-6293.
8. Fribley AM, et al. (2006) Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281:31440-31447.
9. Perez-Galan P, et al. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107:257-264.
10. Gomez-Bougie P, et al. (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67:5418-5424.
11. Nikiforov MA, et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104:19488-19493.
12. Rizzatti EG, et al. (2008) Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 49:798-808.
13. Obeng EA, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107:4907-4916.
14. Oda E, et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053-1058.
15. Fiebiger E, et al. (2004) Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin. Mol Biol Cell 15:1635-1646.
16. Wang Q, Li L, Ye Y (2006) Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. J Cell Biol 174:963-971.
17. Wang Q, Li L, Ye Y (2008) Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem 283:7445-7454.
18. Harding HP, Calfon M, Urano F, Novoa I, Ron D (2002) Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 18:575-599.
19. Shen X, et al. (2001) Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell 107:893-903.
20. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107:881-891.
21. Calfon M, et al. (2002) IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415:92-96.
22. Degterev A, et al. (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3:173-182.
23. Shilatifard A (2006) Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 75:243-269.
24. Weake VM, Workman JL (2008) Histone ubiquitination: Triggering gene activity. Mol Cell 29:653-663.
25. Dantuma NP, Groothuis TA, Salomons FA, Neefjes J (2006) A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J Cell Biol 173:19-26.
26. Wang H, et al. (2004) Role of histone H2A ubiquitination in Polycomb silencing. Nature 431:873-878.
27. Joo HY, et al. (2007) Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 449:1068-1072.
28. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D (2007) The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109:4441-4449.
29. Puthalakath H, et al. (2007) ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129:1337-1349.
30. Mestre-Escorihuela C, et al. (2007) Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109:271-280.
31. Yamashita M, et al. (2008) Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J Exp Med 205:1109-1120.
32. Stock JK, et al. (2007) Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nat Cell Biol 9:1428-1435.
33. Li J, Lee B, Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 281:7260-7270.
34. Knoepfler PS, et al. (2006) Myc influences global chromatin structure. EMBO J 25:2723-2734.
35. Mora-Jensen H, Rizzatti EG, Wiestner A (2006) Resistance to bortezomib develops slowly in MCL cells, extends to the class of proteasome inhibitors, and is associated with decreased proliferation of the resistant cells. Blood 108:4397a.
36. Boyce M, et al. (2005) A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307:935-939.